ATE291914T1 - Zolmitriptanhaltige arzneizusammensetzungen - Google Patents

Zolmitriptanhaltige arzneizusammensetzungen

Info

Publication number
ATE291914T1
ATE291914T1 AT00979765T AT00979765T ATE291914T1 AT E291914 T1 ATE291914 T1 AT E291914T1 AT 00979765 T AT00979765 T AT 00979765T AT 00979765 T AT00979765 T AT 00979765T AT E291914 T1 ATE291914 T1 AT E291914T1
Authority
AT
Austria
Prior art keywords
zolemtript
compositions containing
medicinal compositions
formulation
medicinal
Prior art date
Application number
AT00979765T
Other languages
English (en)
Inventor
Alan Roy Dearn
Sarah Louise Williamson
Simon John Summers
Trevor John Coomber
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10865629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE291914(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE291914T1 publication Critical patent/ATE291914T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT00979765T 1999-12-03 2000-11-28 Zolmitriptanhaltige arzneizusammensetzungen ATE291914T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9928578.5A GB9928578D0 (en) 1999-12-03 1999-12-03 Pharmaceutical formulations
PCT/GB2000/004528 WO2001039772A1 (en) 1999-12-03 2000-11-28 Pharmaceutical formulations containing zolmitriptan

Publications (1)

Publication Number Publication Date
ATE291914T1 true ATE291914T1 (de) 2005-04-15

Family

ID=10865629

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00979765T ATE291914T1 (de) 1999-12-03 2000-11-28 Zolmitriptanhaltige arzneizusammensetzungen

Country Status (28)

Country Link
US (2) US6750237B1 (de)
EP (1) EP1237551B1 (de)
JP (1) JP2003515559A (de)
KR (1) KR100670092B1 (de)
CN (1) CN1222287C (de)
AT (1) ATE291914T1 (de)
AU (1) AU778092B2 (de)
BR (1) BRPI0016138B8 (de)
CA (1) CA2392050C (de)
CZ (1) CZ301528B6 (de)
DE (1) DE60019162T2 (de)
EE (1) EE05305B1 (de)
ES (1) ES2236001T3 (de)
GB (2) GB9928578D0 (de)
HK (3) HK1048442B (de)
HU (1) HU229458B1 (de)
IL (2) IL149578A0 (de)
IS (1) IS2135B (de)
MX (1) MXPA02005319A (de)
NO (1) NO322119B1 (de)
NZ (1) NZ518862A (de)
PL (1) PL200679B1 (de)
PT (1) PT1237551E (de)
RU (1) RU2255736C2 (de)
SK (1) SK287228B6 (de)
UA (1) UA75059C2 (de)
WO (1) WO2001039772A1 (de)
ZA (1) ZA200203704B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8465468B1 (en) 2000-06-29 2013-06-18 Becton, Dickinson And Company Intradermal delivery of substances
GB9928578D0 (en) * 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations
SE0102855D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab Method of treatment
US20050256182A1 (en) * 2004-05-11 2005-11-17 Sutter Diane E Formulations of anti-pain agents and methods of using the same
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
ES2624585T3 (es) * 2004-05-28 2017-07-17 Imaginot Pty Ltd. Sistema de suministro de compuesto terapéutico oral
EP1812428A2 (de) * 2004-11-19 2007-08-01 Teva Pharmaceutical Industries Ltd Zolmitriptan-kristallformen
CN100341504C (zh) * 2004-12-01 2007-10-10 鲁南制药集团股份有限公司 佐米曲普坦速释制剂
AU2006317530B2 (en) * 2005-11-28 2011-09-01 Imaginot Pty Ltd Oral therapeutic compound delivery system
US20100048609A1 (en) * 2006-08-01 2010-02-25 Jacobs Jeffrey W Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
CN101687788A (zh) * 2006-10-19 2010-03-31 奥斯拜客斯制药有限公司 取代的吲哚
KR101517415B1 (ko) 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
CN103402514B (zh) 2010-10-15 2016-01-13 康特拉医药公司 用于治疗运动障碍的血清素受体激动剂组合物
JP6121734B2 (ja) * 2012-02-09 2017-04-26 久光製薬株式会社 マイクロニードル用ゾルミトリプタン含有コーティング組成物及びマイクロニードルデバイス
JP6216768B2 (ja) 2012-04-18 2017-10-18 コンテラ ファーマ アンパルトセルスカブＣｏｎｔｅｒａ Ｐｈａｒｍａ Ａｐｓ 運動障害の管理の改善に適した経口投与可能な医薬製剤
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
KR101624049B1 (ko) 2014-10-29 2016-05-24 연세대학교 산학협력단 사카린을 이용한 용해도를 증가시킨 약제학적 조성물
EP3310360B1 (de) * 2015-06-19 2024-03-27 Beijing Artivila BioPharma Co. Ltd. Chirale spezifische borhaltige verbindungen und deren verwendung in der behandlung von krebs oder amyloidose
WO2017122161A1 (en) 2016-01-15 2017-07-20 Cadila Healthcare Limited An intranasal composition comprising 5ht1b/1d receptor agonists
US11975104B2 (en) 2016-07-11 2024-05-07 Contera Pharma A/S Pulsatile drug delivery system for treating morning akinesia
WO2019126766A1 (en) * 2017-12-21 2019-06-27 Taiwan Liposome Co., Ltd. Sustained-release triptan compositions and method of use the same through subdermal route or the like
US20210322343A1 (en) 2020-04-15 2021-10-21 Farzana Shaheen Nasally administered pharmaceutical composition for the treatment of epilepsy and related disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU219974B (hu) * 1990-06-07 2001-10-28 Astrazeneca Ab, Heterociklusos csoporttal helyettesített indolszármazék, előállítása és a vegyületet hatóanyagként tartalmazó gyógyszerkészítmények
US6255502B1 (en) * 1996-07-11 2001-07-03 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
GB2315673A (en) 1996-08-01 1998-02-11 Merck & Co Inc Treatment of migraine
EP1014943B1 (de) * 1997-02-05 2002-06-19 Jago Research Ag Medizinische aerosolformulierungen
GB9928578D0 (en) * 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations

Also Published As

Publication number Publication date
NO322119B1 (no) 2006-08-14
GB9928578D0 (en) 2000-02-02
NO20022525L (no) 2002-05-28
CA2392050C (en) 2009-11-24
IL149578A0 (en) 2002-11-10
CZ301528B6 (cs) 2010-04-07
GB2373726A (en) 2002-10-02
DE60019162D1 (de) 2005-05-04
JP2003515559A (ja) 2003-05-07
CN1402636A (zh) 2003-03-12
EP1237551B1 (de) 2005-03-30
ES2236001T3 (es) 2005-07-16
DE60019162T2 (de) 2006-02-02
HUP0203597A3 (en) 2005-07-28
HK1048442B (zh) 2005-05-13
GB2373726B (en) 2004-10-20
AU1715701A (en) 2001-06-12
HUP0203597A2 (hu) 2003-02-28
MXPA02005319A (es) 2002-12-06
UA75059C2 (uk) 2006-03-15
CZ20021901A3 (cs) 2002-11-13
NZ518862A (en) 2004-02-27
RU2002117649A (ru) 2004-01-27
HU229458B1 (en) 2013-12-30
IS6394A (is) 2002-05-24
BR0016138A (pt) 2002-08-06
EE05305B1 (et) 2010-06-15
KR20020058051A (ko) 2002-07-12
US7220767B2 (en) 2007-05-22
IL149578A (en) 2008-04-13
HK1048445B (zh) 2005-08-26
NO20022525D0 (no) 2002-05-28
PT1237551E (pt) 2005-07-29
HK1048445A1 (en) 2003-04-04
BR0016138B1 (pt) 2013-09-10
CA2392050A1 (en) 2001-06-07
SK7532002A3 (en) 2002-12-03
SK287228B6 (sk) 2010-03-08
PL357597A1 (en) 2004-07-26
EE200200283A (et) 2003-06-16
US20040214899A1 (en) 2004-10-28
BRPI0016138B8 (pt) 2021-05-25
RU2255736C2 (ru) 2005-07-10
PL200679B1 (pl) 2009-01-30
HK1053430A1 (en) 2003-10-24
US6750237B1 (en) 2004-06-15
HK1048442A1 (en) 2003-04-04
CN1222287C (zh) 2005-10-12
KR100670092B1 (ko) 2007-01-17
IS2135B (is) 2006-08-15
ZA200203704B (en) 2003-10-29
WO2001039772A1 (en) 2001-06-07
AU778092B2 (en) 2004-11-18
GB0214845D0 (en) 2002-08-07
EP1237551A1 (de) 2002-09-11

Similar Documents

Publication Publication Date Title
ATE291914T1 (de) Zolmitriptanhaltige arzneizusammensetzungen
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
TR199901417T2 (xx) Analjezik etkisi olan yeni bile�imler.
ID27504A (id) Formulasi oral baru
GB0005251D0 (en) Therapeutic compounds
SE9504661D0 (sv) New compounds
MY132705A (en) Novel compounds with analgesic effect
YU37602A (sh) Derivat pirolidinacetamida sam ili u kombinaciji za tretman poremećaja cns
DE60019334D1 (de) Antivirale arznei
HUP0301349A2 (hu) IL-11-tartalmú készítmények
NO20004419L (no) Ny anvendelse
HUP9901360A2 (hu) Cimicifuga racemosa-ból származó extraktum alkalmazása
ID28510A (id) Formulasi oral yang baru untuk agonis atau antagonis 5-ht4
ATE301999T1 (de) Racecadotril enthaltende trockene pulverformulierung
RS49599B (sr) Upotreba inhibitora h+, k+-atp-aze i glukokortikoida i farmaceutska formulacija
ATE360428T1 (de) Analgetisches arzneimittel
SE0001916D0 (sv) Novel formulation
HUP0300863A2 (hu) N-(3,5-diklór-2-metoxi-fenil)-4-metoxi-3-(1-piperazinil)-benzolszulfonamid, eljárás elżállítására és a vegyületet tartalmazó gyógyszerkészítmény
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
MY141008A (en) Oral formulations of deoxypeganine and their uses
ATE334675T1 (de) Arzneimittel enthaltend substituierte 2,5- diaminomethyl-1h-pyrrole
UA38889A (uk) Лікувальний засіб "ліварекс" на основі диметоксіуреїдофосфорної кислоти

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1237551

Country of ref document: EP